2024年10月21日（月）～23日（水）ウェスティン都ホテル京都にて開催予定のBioProcess International Asiaにて当社事業開発部・Trimechが口頭発表を行います。

【展示会概要】　https://informaconnect.com/bpi-asia/

【口頭発表】
日時：10月23日（水）16:30-17:00
会場：ウェスティン都ホテル京都
発表タイトル： Pandemic Readiness, Sa-mRNA and LNP Technology Transfer, a US – Japan Collaboratio
発表者：Hamid Trimech（事業開発部）

概要：　In November 2023, MLHW, Japanese Health Authorities, approved the world’s 1st Sa-mRNA Covid-19 vaccine, Kostaive™. As part of the Japanese government pandemic readiness initiative, this new vaccine, developed in collaboration by Arcturus Therapeutics, CSL Seqirus and Meiji Seika Pharma will be manufactured locally in Japan. In September of 2023, a technology transfer of both the mRNA and LNP technologies to a newly established CDMO, ARCALIS Inc. was initiated with a target of completion by fall 2024. This presentation shares how mRNA and LNP manufacturing capability was established in record time and the methodology implemented, issues faced, and lessons learned throughout the transfer of Sa-mRNA/LNP technology to Japan.